W
WAVEMAN · COMPANY
IMRX · Immuneering Corp
> Ask across nine datasets ⌘K
LIVE
TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475
← ALL COMPANIES

IMRX

Immuneering Corp
PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0001790340
C-SUITE BUYING · 2☆ WATCH
INSIDER NET · 180D
$36.0K
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
2
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
74
13F, latest reported quarter
REVENUE GROWTH
-100.0%
XBRL, annual
NET MARGIN
-
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net +$36.0K over 180 days
+$36.0K over 90 days
more than 71% of Pharma & Biotech
CONGRESS
no member of Congress has reported trading it
FUNDS
74 funds added or opened last quarter
more than 55% of Pharma & Biotech
REVENUE
-100.0% year over year
the lowest in Pharma & Biotech
MARGIN
no margin: this company reports no revenue to divide by
BUYBACKS
no share repurchases reported
SHORT
59.4% of shares outstanding short · 20.4 days to cover · settled 2026-07-31
the highest in Pharma & Biotech
THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET
74 funds added or opened positions in the latest 13F quarter, of 113 holders.
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN -19.5%
-19.5%12M
-35%-5%+25%+55%2025-092025-102025-122026-032026-052026-072026-09 2026-01-15 · Schall Thomas J. bought $101.1K2026-01-12 · Feinberg Peter bought $87.0K2025-09-30 · Feinberg Peter bought $52.7K2025-10-03 · Feinberg Peter bought $50.0K2025-09-29 · Feinberg Peter bought $35.9K2026-06-15 · Hall Brett Matthew bought $25.0K2026-01-16 · Brakewood Harold Eugene bought $25.0K2026-06-23 · Zeskind Benjamin J. bought $10.9K2026-01-13 · Neufeld Leah R bought $10.9K2026-01-15 · Hall Brett Matthew bought $10.5K2025-10-01 · Bookman Michael bought $7.0K2025-10-01 · Neufeld Leah R bought $5.1K2025-10-01 · Morales Mallory bought $1.9K
INSIDER BUY
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
Insiders are net buyers of their own stock.
The record shows a net $36.0K bought by insiders over 180 days, 74 funds added last quarter. Every figure is a federal filing, dated the day it became public.
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, Immuneering Corp insiders bought a net $36.0K of stock across 74 Form 4 purchases and sales, with 2 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER
FILED
SHARES
VALUE
Zeskind Benjamin J.
PRESIDENT AND CEO
BUY
2026-06-23
2,400.0
$10.9K
Hall Brett Matthew
CHIEF SCIENTIFIC OFFICER
BUY
2026-06-15
6,035.0
$25.0K
Brakewood Harold Eugene
Chief Business Officer
BUY
2026-01-16
5,250.0
$25.0K
Schall Thomas J.
Director
BUY
2026-01-15
21,645.0
$101.1K
Hall Brett Matthew
CHIEF SCIENTIFIC OFFICER
BUY
2026-01-15
2,298.0
$10.5K
74 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 69 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
FMR LLC
9,704,610.0 sh
$48.4M
BlackRock, Inc.
4,374,020.0 sh
$21.8M
Sanofi
2,708,559.0 sh
$13.5M
VANGUARD CAPITAL MANAGEMENT LLC
2,286,434.0 sh
$11.4M
GEODE CAPITAL MANAGEMENT, LLC
1,370,750.0 sh
$6.8M
SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
FORM 144
No planned-sale notices
No insider has notified an intent to sell. This is the panel to watch after a run-up.
Fund concentration
N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show
Ultra-Small Company Fund
$316.2K POSITION · AS OF 2026-03-31
0.4%
Ultra-Small Company Market Fund
$262.7K POSITION · AS OF 2026-03-31
0.2%
Select Biotechnology Portfolio
$6.4M POSITION · AS OF 2026-02-28
0.1%
iShares Micro-Cap ETF
$699.0K POSITION · AS OF 2026-03-31
0.1%
EQ/T.Rowe Price Health Sciences Portfolio
$66.9K POSITION · AS OF 2026-03-31
0.0%
T. Rowe Price Health Sciences Portfolio
$273.3K POSITION · AS OF 2026-03-31
0.0%
SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK
Clinical pipeline
ClinicalTrials.gov · 3 registered trials, 2 still enrolling or running — a status change here is dated weeks before the press release
1
Phase 3
1 ACTIVE
2
Multi-phase
1 ACTIVE
TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-122022-12
REVENUE$0$317.0K
GROSS PROFIT$0$158.8K
OPERATING INCOME$-59.4M$-64.1M$-58.4M$-51.7M
NET INCOME$-56.0M$-61.0M$-53.5M$-50.5M
EPS (DILUTED)-1.27-2.04-1.88-1.91
OPERATING CASH FLOW$-45.3M$-55.0M$-49.0M$-44.1M
CASH$128.6M$36.1M$59.4M$72.6M
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-06 ALL SYSTEMS LIVE FOR MACHINES →